ВАН Шаомэн (US),МАЛЕК Сами (US),ЛУН Цзяньтин (US),УИЛЛЕТТ Питер (US)
申请号：
RU2012147597/15
公开号：
RU2012147597A
申请日:
2011.04.05
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating a patient with leukemia, which comprises administering a therapeutically effective amount of a MDM2 inhibitor selected from the group consisting of: or a pharmaceutically acceptable salt thereof to a patient, where the patients cells contain an activating FLT3 mutatsiey.2. A method of screening a patient with leukemia, for the treatment inhibitor MDM2, selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein the method comprises: (a) taking a biological sample from a patient (b) determining whether the biological sample FLT3 an activating mutation and (c) selecting the patient for treatment if the biological sample comprises an activating FLT3 mutatsiey.3. A method according to claim 2, further comprising administering to the patient a therapeutically effective amount MDM2.4 inhibitor. A method for predicting the outcome of patients with leukemia, wherein the method comprises: (a) taking a biological sample from a patient and (b) determining whether the biological sample FLT3 an activating mutation, thus revealing FLT3 an activating mutation, demonstrates that administering a therapeutically effective amount of a MDM2 inhibitor selected from the group consisting of: or a pharmaceutical salt thereof, to a patient cause a beneficial therapeutic otvet.5. A method of treating a patient with leukemia, wherein the method comprises: (a) taking a biological sample from a patient (b) determining whether the biological sample comprises an activating mutation of FLT3 and (c) administering to the patient a therapeutically effective amount of a MDM2 inhibitor selected from the group consisting of: or a pharmaceutically acceptable salt thereof to a patient, if the biological image1. Способ лечения больного лейкозом, который включает введение терапевтически эффективного количества ингибитора MDM2, выбранного из группы, состоящей из:или его фармацевтически приемлемой соли, пациенту, где клетки пациента содержат FLT3 с ак
